Skip to main content

Table 2 Mean changes from baseline for DAS28 and MBDA score during treatment with a tight-control strategy initiating MTX+plac or MTX+pred

From: The multi-biomarker disease activity test for assessing response to treatment strategies using methotrexate with or without prednisone in the CAMERA-II trial

  DAS28 MBDA score
  MTX+plac MTX+pred MTX+plac MTX+pred
Time-point (month) n Mean change N Mean change n Mean change n Mean change
1 16 − 0.3
P = 0.243
11 − 1.9
P < 0.001
18 − 3
P = 0.265
14 − 12
P = 0.013
2 15 − 0.7
P = 0.021
11 − 2.4
P < 0.001
17 − 3
P = 0.251
14 − 11
P = 0.02
3 22 − 1.3
P < 0.001
13 − 3.0
P < 0.001
25 − 5
P = 0.093
17 − 15
P = 0.002
4 13 − 1.8
P = 0.001
10 − 3.9
P < 0.001
17 − 9
P = 0.029
14 − 19
P = 0.003
5 15 − 2.2
P < 0.001
10 − 4.2
P < 0.001
18 − 12
P = 0.006
12 − 20
P = 0.003
6 18 − 2.8
P < 0.001
12 − 3.0
P = 0.001
29 − 20
P < 0.001
19 − 16
P = 0.001
9 17 − 2.7
P < 0.001
12 − 3.2
P = 0.001
24 − 24
P < 0.001
17 − 20
P = 0.001
12 31 − 2.8
P < 0.001
28 − 3.1
P < 0.001
44 − 20
P < 0.001
37 − 16
P < 0.001
  1. Each n value indicates number of patients from the study cohort (total N = 92) with available data at that time-point. P values are for changes from baseline by t test
  2. DAS28 28-joint-based disease activity score, MBDA multi-biomarker disease activity, MTX+plac the methotrexate and placebo strategy, MTX+pred the methotrexate and prednisone strategy